IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Gastroenterology and Hepathology

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MEG.0000000000000436PMID 26181108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.

  2014cited by this paper
• Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

  2014cited by this paper
• Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century.

  2014cited by this paper
• Prise en charge des patients atteints de maladie inflammatoire chronique intestinale en France : une enquête nationale auprès des gastro-entérologues libéraux Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists

  2014cited by this paper
• Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis.

  2014cited by this paper
• Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists.

  2014cited by this paper
• Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century.

  2014cited by this paper
• Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.

  2014cited by this paper
• Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

  2014cited by this paper
• Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years

  2014cited by this paper
• Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

  2014cited by this paper
• Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

  2013cited by this paper
• Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.

  2013cited by this paper
• Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

  2013cited by this paper
• Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper

  2013cited by this paper
• Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab

  2013cited by this paper
• Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

  2013cited by this paper
• Infliximab for the treatment of psoriasis in the U.K.: 9 years’ experience of infusion reactions at a single centre

  2012cited by this paper
• The decline of anti‐drug antibody titres after discontinuation of anti‐TNFs: implications for predicting re‐induction outcome in IBD

  2012cited by this paper
• Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions

  2012cited by this paper
• Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies

  2012cited by this paper
• Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.

  2012cited by this paper
• Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab

  2012cited by this paper
• Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction

  2012cited by this paper
• Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

  2011cited by this paper
• Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a Crohn's disease patient.

  2011cited by this paper
• How to manage hypersensitivity reactions to biological agents?

  2011cited by this paper
• Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to mAbs : 105 desensitizations in 23 patients , from evaluation to treatment

  2011cited by this paper
• A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

  2010cited by this paper
• Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions

  2010cited by this paper
• European Society

  2010cited by this paper
• Safety of infliximab in Crohn's disease: A large single‐center experience

  2010cited by this paper
• The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

  2010cited by this paper
• Serum sickness, encephalitis and other complications of anti-cytokine therapy.

  2009cited by this paper
• Prevention of acute adverse events related to infliximab infusions in pediatric patients

  2009cited by this paper
• Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.

  2009cited by this paper
• Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

  2009cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists

  2007cited by this paper
• American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

  2007cited by this paper
• EDITOR’S QUIZ: GI SNAPSHOT

  2007cited by this paper
• Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

  2007cited by this paper
• Successful retreatment with infliximab in patients with prior severe infusion reactions

  2006cited by this paper
• Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.

  2006cited by this paper
• Adverse side‐effects to biological agents

  2006cited by this paper
• Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions

  2006cited by this paper
• Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis

  2005cited by this paper
• Accoutumance médicamenteuse à l'infliximab dans la maladie de Crohn

  2005cited by this paper
• [Desensitisation to infliximab in patients with Crohn's disease].

  2005cited by this paper
• An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease

  2004cited by this paper
• A Pilot Study of Adalimumab in Infliximab-Allergic Patients

  2004cited by this paper
• Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.

  2004cited by this paper
• Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.

  2004cited by this paper
• The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience

  2003cited by this paper
• Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• General considerations for skin test procedures in the diagnosis of drug hypersensitivity

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions

  2001cited by this paper
• Criteria of evaluation and of interpretation of Sepharose drug IgE‐RIA to anaesthetic drugs

  1999cited by this paper
• Isolation and characterization of proteic allergens in refined peanut oil

  1998cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Tools for Etiologic Diagnosis of Drug-Induced Allergic Conditions

  2023cites this paper
• Anaphylaxis to Drugs, Biological Agents, and Vaccines.

  2022cites this paper
• Skin tests in the work‐up of cutaneous adverse drug reactions: A review and update

  2022cites this paper
• Hypersensitivity reactions to biologicals: An EAACI position paper

  2021cites this paper
• Immunogenicity of TNF-Inhibitors

  2020cites this paper
• Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs.

  2020cites this paper
• The Prevalence of Hypersensitivity Reactions to Antirheumatic Biological Agents and Results of the Skin Tests: Experience of a Tertiary Referral Allergy Center in Turkey

  2020cites this paper
• Hypersensitivity reactions to biologics used in rheumatology

  2019cites this paper
• Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions

  2018cites this paper
• Interesting Case of Infliximab IV Type Hypersensitivity.

  2018cites this paper
• In Vitro and In Vivo Tests in Cutaneous Adverse Drug Reactions

  2018cites this paper
• Akute Überempfindlichkeitsreaktionen auf monoklonale Antikörper zur zielgerichteten Therapie

  2018cites this paper
• Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies

  2018cites this paper
• Immunogenicity of therapeutic antibodies: Immunological mechanisms & clinical consequences

  2017cites this paper
• Immunological Mechanisms of Drug Hypersensitivity.

  2017cites this paper
• Monoclonal Antibodies Hypersensitivity: Prevalence and Management.

  2017cites this paper
• Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Immunogenicity of therapeutic antibodies

  2017cites this paper
• Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.

  2017cites this paper
• Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies

  2017cites this paper
• Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.

  2017cites this paper